Brief: ImmuCell Announces An Agreement Covering The Formulation And Aseptic Filling Of Syringes For Re-Tain

ImmuCell

11/09/2019 13:06

Sept 11 (Reuters) - ImmuCell Corp  ICCC.O :
    * IMMUCELL ANNOUNCES AN AGREEMENT COVERING THE FORMULATION
AND
ASEPTIC FILLING OF SYRINGES FOR RE-TAIN™
    * IMMUCELL CORP - ENTERED INTO A NEW AGREEMENT WITH NORBROOK
LABORATORIES, LIMITED OF NEWRY, NORTHERN IRELAND
    * IMMUCELL CORP - NEW AGREEMENT (WHICH REPLACES AN EXPIRING
AGREEMENT) EXPIRES AS OF DECEMBER 31, 2021
    * IMMUCELL CORP - AGREEMENT ALLOWS FOR PRODUCT ORDERED
BEFORE
EXPIRATION DATE TO BE DELIVERED INTO EARLY PART OF 2022
    * IMMUCELL - CO'S RE-TAIN PRODUCTION FACILITY HAS BEEN
EQUIPPED TO
MANUFACTURE DRUG SUBSTANCE WITH A COMMERCIAL SALES VALUE OF
ABOUT $10 MILLION PER YEAR
    * IMMUCELL CORP - NEW AGREEMENT WITH NORBROOK COVERS
FORMULATION
AND ASEPTIC FILLING OF DRUG PRODUCT WITH A COMMERCIAL SALES
VALUE OF ABOUT $7 MILLION
    * IMMUCELL CORP - ANTICIPATES ACHIEVING FDA APPROVAL OF
RE-TAIN™
DURING 2021.

Source text for Eikon:  ID:nGNX3Gf7L1 
Further company coverage:  ICCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))